Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Rating of “Buy” by Brokerages

Shares of Biodesix, Inc. (NASDAQ:BDSX) have received a consensus rating of “Buy” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $3.06.

A number of research analysts recently weighed in on BDSX shares. Scotiabank began coverage on Biodesix in a research note on Monday, September 16th. They set a “sector outperform” rating and a $3.00 price target on the stock. Craig Hallum began coverage on Biodesix in a research note on Friday, July 26th. They issued a “buy” rating and a $3.00 price objective for the company.

Biodesix Stock Down 0.6 %

NASDAQ BDSX opened at $1.69 on Wednesday. The company has a current ratio of 3.28, a quick ratio of 3.28 and a debt-to-equity ratio of 0.99. Biodesix has a 1-year low of $1.15 and a 1-year high of $2.21. The company has a 50 day moving average of $1.75 and a 200-day moving average of $1.58. The company has a market cap of $245.35 million, a price-to-earnings ratio of -3.67 and a beta of 1.22.

Biodesix (NASDAQ:BDSX) last posted its earnings results on Wednesday, August 7th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. Biodesix had a negative net margin of 73.08% and a negative return on equity of 505.95%. The firm had revenue of $17.93 million for the quarter, compared to analysts’ expectations of $16.05 million. During the same quarter in the previous year, the firm posted ($0.17) earnings per share. On average, equities research analysts expect that Biodesix will post -0.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Perceptive Advisors LLC purchased a new position in shares of Biodesix during the second quarter valued at approximately $3,326,000. CVI Holdings LLC bought a new stake in Biodesix during the second quarter worth $59,000. Farallon Capital Management LLC bought a new stake in Biodesix during the second quarter worth $2,874,000. AIGH Capital Management LLC lifted its holdings in Biodesix by 74.0% during the second quarter. AIGH Capital Management LLC now owns 5,779,812 shares of the company’s stock worth $8,843,000 after acquiring an additional 2,458,727 shares during the period. Finally, Opaleye Management Inc. lifted its holdings in Biodesix by 7.7% during the first quarter. Opaleye Management Inc. now owns 534,657 shares of the company’s stock worth $765,000 after acquiring an additional 38,157 shares during the period. Hedge funds and other institutional investors own 20.96% of the company’s stock.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.